Pulmonary Arterial Hypertension

This is a serious condition where the blood pressure in the arteries that carry blood from the heart to the lungs becomes dangerously high. It's a progressive disease, meaning it tends to get worse over time. It can make it hard for the heart to pump blood effectively.

Condition

What people with Pulmonary Arterial Hypertension report

Every report comes from a Lived member, sent anonymously.

Have you tried Viagra (Sildenafil) for Pulmonary Arterial Hypertension?

NameHow it went

About Pulmonary Arterial Hypertension

What It Is

Pulmonary arterial hypertension (PAH) is a rare, long-term disease of the small arteries in the lungs. The walls of these vessels thicken and narrow, so blood has a harder time passing through them and the pressure inside the lung arteries rises. The right side of the heart, which pumps blood into the lungs to pick up oxygen, has to work harder against that pressure. Over time it can enlarge and weaken, a problem called right heart failure. The first symptom is usually shortness of breath during activities that used to feel easy, often with unusual tiredness. As the disease advances, people may notice chest pain or pressure, dizziness or fainting with exertion, a pounding or racing heartbeat, and swelling in the ankles, legs or abdomen. Because these symptoms are shared by many more common conditions, PAH is often diagnosed only after months or even years. PAH is one specific type of pulmonary hypertension, the broader term for high pressure in the lung arteries. Most pulmonary hypertension is caused by disease of the left side of the heart or by lung diseases such as chronic obstructive pulmonary disease (COPD), and it is managed by treating that underlying problem. PAH, also called group 1 pulmonary hypertension, is different: the disease starts in the lung arteries themselves, and it has its own set of treatments.

Causes & Risk Factors

In many people with PAH, no cause is found. This is called idiopathic PAH. A small share of cases are heritable, caused by a change in a gene, most often one called BMPR2 (bone morphogenetic protein receptor type 2). When a gene change is found, relatives can be offered genetic counseling and, if they carry it, regular screening. Some substances are firmly linked to PAH, including methamphetamine, certain appetite-suppressant drugs such as fenfluramine, and dasatinib, a leukemia medicine. PAH can also develop alongside other conditions, most notably systemic sclerosis (scleroderma) and related connective tissue diseases, HIV, liver disease that raises pressure in the liver's blood supply (portal hypertension), heart defects present from birth, and schistosomiasis, a parasitic infection. PAH is more common in women than in men. PAH can appear at any age, and in recent registries many people are over 60 when diagnosed. Having one of these risk factors does not mean someone will develop PAH, and it is never a matter of personal blame.

How It's Diagnosed

The workup usually starts with tests that look for more common causes of breathlessness: blood tests, an electrocardiogram (ECG), a chest X-ray and breathing tests. An echocardiogram, an ultrasound of the heart, is the key screening test. It estimates the pressure in the lung arteries and shows whether the right side of the heart is under strain. It can make pulmonary hypertension more or less likely, but it cannot confirm it. Confirmation requires right heart catheterization, in which a thin tube is passed through a vein into the right side of the heart and the lung artery to measure pressures directly. Pulmonary hypertension is present when the average (mean) pressure in the lung arteries is above 20 mmHg at rest; in healthy people it is 20 or lower. To call it PAH, two more results matter. The resistance to blood flow through the lungs must be high (above 2 Wood units), and a pressure reflecting the left side of the heart, called the wedge pressure, must be 15 mmHg or lower, which shows the problem is not coming from the left heart. Further tests, including a CT scan of the chest, a lung scan for old blood clots, blood tests for HIV, liver and autoimmune disease, and a urine drug screen, look for a cause and rule out other types of pulmonary hypertension. During the catheterization, people with idiopathic, heritable or drug-related PAH also have a vasoreactivity test, which checks whether the lung arteries relax in response to a short-acting test medicine. Because the evaluation is complex, it is best done at a specialist pulmonary hypertension center.

Treatment Options

There is currently no cure for PAH, but treatment has improved considerably. Today's medicines can ease breathlessness, improve how far and how comfortably people can walk, and slow the disease, reducing episodes of worsening and hospital stays. Combinations work better than single medicines, so most people start with two pills at once, unless other heart or lung conditions make a single medicine a safer start: an endothelin receptor antagonist such as ambrisentan (Letairis) or macitentan (Opsumit), which blocks a natural substance that constricts the vessels, and a phosphodiesterase-5 (PDE-5) inhibitor, sildenafil (Revatio) or tadalafil (Adcirca), which helps the vessels relax. People who are very unwell at diagnosis usually also start a continuous infusion of a prostacyclin medicine, epoprostenol or treprostinil, given by a small pump into a vein or under the skin. The team reassesses within a few months and adds treatment if the person is not yet at low risk. Options include other prostacyclin-pathway medicines taken as pills (selexipag or oral treprostinil) or inhaled several times a day, switching from a PDE-5 inhibitor to riociguat, a pill that relaxes the lung arteries through a related pathway, and sotatercept (Winrevair), an injection given every three weeks that targets the abnormal growth of the vessel walls. In its main trial, adding sotatercept to existing treatment improved walking distance and reduced worsening; studies of its long-term effects are ongoing. Each option has trade-offs. Endothelin receptor antagonists can cause fluid retention and anemia, and they can cause birth defects, so pregnancy testing and reliable contraception are required. PDE-5 inhibitors commonly cause headache and flushing, and they must never be combined with nitrate heart medicines such as nitroglycerin, because blood pressure can fall dangerously. Prostacyclin medicines often cause headache, flushing, jaw pain, nausea and diarrhea, which tend to ease with time. Infusions are the most powerful option but mean living with a pump and line around the clock, with a risk of line infections for infusions into a vein and site pain for infusions under the skin. Sotatercept raises the risk of bleeding, most often nosebleeds or gum bleeding, and needs regular blood count checks. A small group of people with idiopathic, heritable or drug-related PAH respond strongly to the vasoreactivity test. They may do well on high doses of calcium channel blockers, common blood pressure medicines such as nifedipine or diltiazem, but need close follow-up because the response can fade. Supportive care matters too: supervised exercise training, oxygen if blood oxygen is low, diuretics (water pills) for fluid buildup, treatment of iron deficiency, vaccinations and psychological support. Blood thinners are not routinely recommended. If the disease keeps progressing despite full treatment, a lung transplant, or occasionally a heart and lung transplant, is an option for selected people, and referral is often discussed early.

What to Expect

PAH is a lifelong condition that tends to progress, but the pace varies widely from person to person. Survival has improved over recent decades, yet PAH remains a serious illness that shortens life for many people. The best guide to an individual outlook is how someone responds to treatment over the first months and years. Care is usually shared with a specialist pulmonary hypertension center, with visits every few months. Each visit estimates risk from a few key measures: how much activity brings on symptoms (called functional class), how far a person can walk in six minutes, and a blood test called BNP or NT-proBNP, which rises when the heart is under strain. Echocardiograms, and sometimes repeat catheterizations, guide bigger decisions. The goal is to reach and stay at low risk, and treatment is stepped up when that goal is not met. Daily life involves medicine routines that can be demanding, especially inhaled treatments several times a day or a continuous infusion. Many people stay active within their limits, and regular, moderate activity is encouraged once the team agrees on a safe level. High altitude and air travel can lower oxygen levels, so trips are worth discussing in advance. Pregnancy can be life-threatening for both mother and baby in PAH, so guidelines advise against it and recommend highly effective contraception. Anyone hoping to have children should talk with the team early. Living with a serious and often invisible illness can be isolating, and counseling and patient support groups help many people adjust.

When to Seek Help

See a doctor if you become short of breath during activities that used to be easy, or have unexplained fatigue, chest discomfort or dizziness with exertion, particularly if you have a risk factor such as scleroderma, a family history of PAH or liver disease. People at high risk, including those with scleroderma and relatives of someone with heritable PAH, are often offered yearly screening. If you have PAH, contact your pulmonary hypertension team promptly for fainting or near-fainting, breathlessness that is getting worse, new or increasing swelling in the legs or abdomen, rapid weight gain, or coughing up blood. Call 911 for chest pain with shortness of breath that is severe, comes on at rest or does not ease when you stop and rest. If you receive a continuous infusion, an interruption (a pump failure or alarm, or a blocked, leaking or dislodged line) is an emergency, because suddenly stopping the medicine can be life-threatening. Follow your center's pump plan at once, and call 911 if the infusion cannot be restarted right away.

Questions to Ask Your Doctor

  1. 1.What type of pulmonary hypertension do I have, and what tests showed whether something is causing it?
  2. 2.What is my current risk level, and which results will tell us whether treatment is working?
  3. 3.Which medicines do you recommend starting with, and what side effects should I expect in the first weeks?
  4. 4.Should I or my relatives have genetic counseling or screening?
  5. 5.What do I need to know about pregnancy, contraception, travel and exercise with PAH?

Last reviewed • Oct 2026

Educational content, not medical advice.